益气活血解毒汤联合靶向药物治疗气虚血瘀型中晚期非小细胞肺癌临床研究  

Clinical Study on Chinese Herbal Medicine Combined with Targeted Drugs for Middle-Advanced Non-Small Cell Lung Cancer of Qi Deficiency with Blood Stasis Type

作　　者：年立全 范娟 孙亚飞 李海明 NIAN Liquan;FAN Juan;SUN Yafei;LI Haiming

机构地区：[1]驻马店市中心医院呼吸与危重医学科,河南驻马店463000 [2]驻马店市中心医院放疗科,河南驻马店463000 [3]驻马店市中心医院中西医结合科,河南驻马店463000

出　　处：《新中医》2021年第22期144-147,共4页New Chinese Medicine

摘　　要：目的:观察益气活血解毒汤联合靶向药物治疗气虚血瘀型中晚期非小细胞肺癌的近期疗效。方法:选取73例中晚期非小细胞肺癌患者,根据随机数字表法分为研究组37例和对照组36例。对照组行靶向药物吉非替尼口服治疗,研究组在对照组的基础上加服益气活血解毒汤治疗。2组均连续治疗2个月,观察比较2组临床疗效,2组治疗前后血清癌胚抗原(CEA)、糖类抗原125(CA125)和细胞角质蛋白19片段抗原21-1(Cyfra21-1)等肿瘤标志物水平变化,并根据多维疲乏症状量表-简短版(MFSI-SF)评估2组患者癌因性疲乏程度,根据卡氏功能评分量表(KPS)评估2组患者生活质量。结果:研究组控制率为100%,对照组为88.89%,2组比较,差异有统计学意义(P<0.05)。治疗后,2组血清CEA、CA125、Cyfra21-1水平均较治疗前降低(P<0.05),且研究组各项指标均低于对照组(P<0.05)。治疗后,2组MFSI-SF评分较治疗前降低(P<0.05),KPS评分较治疗前升高(P<0.05),且研究组MFSI-SF评分低于对照组(P<0.05),KPS评分高于对照组(P<0.05)。结论:益气活血解毒汤联合靶向药物治疗气虚血瘀型中晚期非小细胞肺癌近期疗效较好,可降低血清肿瘤标志物水平及癌因性疲乏程度,改善患者生活质量。Objective:To observe the short-term effect of Chinese herbal medicine combined with targeted drugs for patients with middle-advanced non-small cell lung cancer of qi deficiency with blood stasis type.Methods:A total of73 cases of patients with middle-advanced non-small cell lung cancer were selected and divided into the study group and the control group according to the random number table method,37 and 36 cases in each group respectively.The control group was given the oral administration of the targeted drug gefitinib,and the study group was additionally treated with Yiqi Huoxue Jiedu tang based on the treatment of the control group.Both groups were treated for two months.The changes in the contents of tumor markers including carcinoembryonic antigen(CEA),carbohydrate antigens(CA125)and cytokeratin19 fragment antigen 21-1(Cyfra21-1)in serum before and after treatment as well as the clinical effect in the two groups were observed and compared.The cancer-related fatigue degree in the two groups was evaluated by Multidimensional Fatigue Symptom Scale-Short Form(MFSI-SF),and the quality of life was evaluated by Karnofsky Performance Status(KPS).Results:The control rate was 100%in the study group and 88.89%in the control group,the difference being significant(P<0.05).After treatment,the contents of CEA,CA125 and Cyfra21-1 in serum in the two groups were decreased when compared with those before treatment(P<0.05),and all the above indexes in study group were lower than those in control group(P<0.05).After treatment,MFSI-SF scores in the two groups were decreased when compared with those before treatment(P<0.05),and KPS scores were increased(P<0.05);the MFSI-SF score in the study group was lower than that in the control group(P<0.05),and the KPS score was higher(P<0.05).Conclusion:The therapy of Yiqi Huoxue Jidu tang combined with targeted drugs has a good short-term effect on patients with patients with middle-advanced non-small cell lung cancer of qi deficiency with blood stasis type,which can reduce the concentrati

关 键 词：非小细胞肺癌 益气活血解毒汤 靶向药物 肿瘤标志物 

分 类 号：R734.2[医药卫生—肿瘤]